GSK Plc
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Values in USD · ADR · Reports in GBP
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The companys wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The companys nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Did you know?
Trading 32% above its estimated fair value of $34.50.
Current Price
$50.90
-1.38%GoodMoat Value
$34.50
32.2% overvaluedProfile
Valuation (TTM)
Market Cap$103.72B
P/E13.09
EV—
P/B4.57
Shares Out2.04B
P/Sales2.34
Revenue$44.31B
EV/EBITDA12.73
GSK Plc (GSK) Stock Analysis
Market Cap$103.72B
Current Price$50.90
P/E Ratio13.09
Forward P/E—
PEG Ratio1.48
EPS$3.75
Book Value$11.14
P/B Ratio4.57
GSK Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use -0.6% FCF growth (CAGR)
Cash vs Debt
Net Debt: 19.4B
Revenue
44.4B
FY19
33.4B
FY20
32.9B
FY21
35.3B
FY22
38.4B
FY23
39.2B
FY24
44.1B
FY25
Net Income
6.1B
FY19
7.9B
FY20
5.8B
FY21
18.0B
FY22
6.2B
FY23
3.2B
FY24
7.7B
FY25
GSK 52-Week Range
$34.83
$60.68
50-Day MA: $55.51200-Day MA: $47.61
Did you know?
Earnings per share grew at a 4.0% CAGR.
GSK Plc (GSK) Financial Summary
GSK Plc (GSK) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. The stock currently trades at $50.90 with a market capitalization of $103.72B.
Key valuation metrics include a P/E ratio of 13.09, price-to-book ratio of 4.57, and EPS of $3.75. The company reports a profit margin of 17.8% and return on equity of 34.7%.
GSK Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $103.72B |
| P/E Ratio | 13.09 |
| EPS | $3.75 |
| P/B Ratio | 4.57 |
| P/S Ratio | 2.34 |
| EV/EBITDA | 12.73 |
| Dividend Yield | 3.34% |
| Profit Margin | 17.8% |
| Return on Equity | 34.7% |
| Debt/Equity | 1.05 |
GSK Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $44.41B | $6.11B |
| FY20 | $33.36B | $7.88B |
| FY21 | $32.93B | $5.85B |
| FY22 | $35.33B | $18.02B |
| FY23 | $38.39B | $6.24B |
| FY24 | $39.22B | $3.22B |
| FY25 | $44.14B | $7.72B |
GSK Plc (GSK) Valuation
Based on GoodMoat's DCF model, GSK Plc has a fair value estimate of $34.50. At the current price of $50.90, the stock appears 47.5% overvalued relative to our intrinsic value estimate.
GSK Quality Indicators
GSK Plc maintains a profit margin of 17.8% and an operating margin of 24.3%. Return on equity stands at 34.7%. The current ratio is 0.82. Debt-to-equity ratio is 1.05.
About GSK Plc
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The companys wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The companys nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
GSK Free Cash Flow
GSK Plc generated $8.67B in trailing twelve-month free cash flow, representing an FCF yield of 8.36%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
GSK Shares Outstanding
GSK Plc has 2.04 billion shares outstanding at a share price of $50.90, giving it a market capitalization of $103.72B.